Showing 8541-8550 of 10139 results for "".
- Lithera to Present at the 13th Annual Needham Healthcare Conferencehttps://practicaldermatology.com/news/20140402-lithera_to_present_at_the_13th_annual_needham_healthcare_conference/2459280/Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that George Mahaffey, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent pro
- Restoration Robotics Launches ARTAS Robotic System For Hair Restorationhttps://practicaldermatology.com/news/20140326-restoration_robotics_launches_artas_robotic_system_for_hair_restoration/2459294/
- FDA Approves Otezla to Treat Psoriatic Arthritishttps://practicaldermatology.com/news/20140321-fda_approves_otezla_to_treat_psoriatic_arthritis/2459301/The FDA approved Otezla (
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Sciton Announces Launch of Halo at AAD Annual Meetinghttps://practicaldermatology.com/news/20140320-sciton_announces_launch_of_halo_at_aad_annual_meeting/2459309/
- Ferndale Healthcare Announces Partnership with Colon Cancer Alliancehttps://practicaldermatology.com/news/20140318-ferndale_healthcare_announces_partnership_with_colon_cancer_awareness/2459313/Ferndale Healthcare's RectiCare® Cream, intended to resolve all discomfort from rectal and anal conditions such as hemorrhoids and anal fissures, urges colon screening for cancer before individuals reach for their brand. The brand wants to promote individuals to not rush to treat when bleeding an
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/
- Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officerhttps://practicaldermatology.com/news/20140305-aquavit_pharmaceuticals_appoints_david_j_goldberg_as_chief_medical_officer/2459324/Aquavit Pharmaceuticals, Inc., appointed David J. Goldberg, MD, JD as its Chief Medical Officer. Dr. Goldberg is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit,